Efatutazone

{{Drugbox | Verifiedfields = changed | verifiedrevid = 477002123 | IUPAC_name = 5-[[4-[[2-(5-ethylpyridin-2-yl)ethoxy]methyl]phenyl]methyl]-1,3-thiazolidine-2,4-dione | image = Efatutazone_structure.png | width = 250 | CAS_number = 189108-07-0 | ATC_prefix = none | PubChem = 9829520 | ChemSpiderID = 8005510 | UNII = 0V5436JA4W | KEGG = D08995 | ChEMBL = 2103878 | C=21 | H=24 | N=2 | O=3 | S=1 | smiles = CCc1ncc(Cc2ccc(cc2)COCC3C(=O)NC(=O)S3)cc1 | StdInChI = 1S/C21H24N2O3S/c1-2-17-11-12-18(22-13-17)10-15-3-5-16(6-4-15)14-26-9-8-19-20(24)23-21(25)27-19/h3-6,11-13,19H,2,8-10,14H2,1H3,(H,23,24,25) | StdInChIKey = QXJXKJXKJZQZQX-UHFFFAOYSA-N }}

Efatutazone is a thiazolidinedione derivative that acts as a peroxisome proliferator-activated receptor (PPAR) agonist, specifically targeting the PPARγ subtype. It has been investigated for its potential use in the treatment of various types of cancer, including breast cancer, prostate cancer, and thyroid cancer.

Mechanism of Action

Efatutazone functions by activating PPARγ, a type of nuclear receptor that regulates the expression of genes involved in glucose and lipid metabolism, as well as cell differentiation and apoptosis. By binding to PPARγ, efatutazone modulates the transcription of genes that can inhibit tumor growth and induce cancer cell differentiation and apoptosis.

Clinical Research

Efatutazone has been the subject of several clinical trials aimed at evaluating its efficacy and safety in cancer treatment. Early-phase trials have shown some promise, particularly in combination with other anticancer agents. However, further studies are needed to fully establish its therapeutic potential and to determine the optimal dosing regimens.

Pharmacokinetics

The pharmacokinetic profile of efatutazone includes its absorption, distribution, metabolism, and excretion. It is orally bioavailable and undergoes hepatic metabolism. The half-life and clearance rates are important factors in determining the dosing schedule for patients.

Side Effects

As with other thiazolidinediones, efatutazone may cause side effects such as weight gain, edema, and an increased risk of heart failure. Monitoring of patients for these adverse effects is crucial during treatment.

Regulatory Status

As of the latest updates, efatutazone has not been approved by major regulatory agencies such as the Food and Drug Administration (FDA) for general clinical use. It remains an investigational drug, primarily used in clinical trial settings.

Also see

• Thiazolidinedione
• PPARγ
• Cancer treatment
• Clinical trial